Horizon Therapeutics (HZNP) and Alpine Immune Sciences (ALPN) on Thursday entered into an exclusive agreement to develop novel protein-based therapies for...
...
Peter A. Thompson, 10% Owner, Director, on September 17, 2021, executed a purchase for 1,010,637 shares in Alpine Immune Sciences (ALPN) for $9,499,988....
Jay Venkatesan, 10% Owner, Director, on September 17, 2021, sold 400,000 shares in Alpine Immune Sciences (ALPN) for $3,760,000. Following the Form 4...
| Address | 188 East Blaine Street Seattle, Washington 98102 |
| Phone | +1.206.788.4545 |
| Number of Employees | 48 |
| Recent SEC Filing | 01/06/2022 4 |
| Executive Chairman & Chief Executive Officer | Mitchell H. Gold |
| President & Head-Research & Development | Stanford L. Peng |
| Finance Director | Thaedra Thullberry |
| Chief Financial Officer, Secretary & Senior VP | James Paul Rickey |
| Price Open | $8.35 |
| Previous Close | $8.47 |
| 52 Week Range | $7.87 - 15.14 |
| Market Capitalization | $245.4 M |
| Shares Outstanding | 29.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/17/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.73 |
| Beta vs. S&P 500 | N/A |
| Revenue | $705.0 K |
| Net Profit Margin | -169.03% |
| Return on Equity | -58.85% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
